Xiidra operates in the pharmaceutical industry, focusing on the treatment of dry eye disease (DED). The company offers lifitegrast ophthalmic solution 5%, an FDA-approved prescription medication specifically designed to alleviate the signs and symptoms of DED. Xiidra serves patients suffering from chronic dry eye conditions, providing a unique solution that targets the inflammation causing the disease, unlike over-the-counter eye drops that merely lubricate the eyes for temporary relief. The company primarily targets commercially insured patients, offering cost-saving programs that can reduce out-of-pocket expenses to as low as $0 per month for those with a prescription. Xiidra's business model revolves around prescription sales and partnerships with healthcare providers to ensure widespread availability and affordability of their product. Revenue is generated through the sale of the prescription eye drops and through insurance reimbursements. The market for Xiidra includes ophthalmologists, optometrists, and patients with chronic dry eye disease, particularly those seeking long-term relief from their symptoms.

Keywords: dry eye disease, lifitegrast, ophthalmic solution, FDA-approved, inflammation, prescription medication, cost-saving, chronic condition, eye drops, healthcare.